All News
Methotrexate - an old trusted friend who deserves better
Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.
Read Article
Clinically suspect arthralgias: justified or artefact?
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.
Read Article
Are T cells the missing link in pre-clinical RA?
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Read Article
Are T cells the missing link in pre-clinical RA?
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Dr.Najm ( @AurelieRheumo ) shares #EULAR23 presentations on this topic.
https://t.co/qVyDp6Gs2y https://t.co/mqxNLIxShd
Links:
Dr. John Cush RheumNow ( View Tweet)
RA and cancer risk in the biologic era
RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era.
https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly
Links:
Dr. John Cush RheumNow ( View Tweet)
AI in RA: the story grows along the patient pathway
The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA.
https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan synovialjoints ( View Tweet)
The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2
Dr. Antoni Chan synovialjoints ( View Tweet)
Better at Predicting RA from MRI: Humans or Computers?
https://t.co/xRVatfiRKS https://t.co/Gwypq8lcdl
Links:
Dr. John Cush RheumNow ( View Tweet)
JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
Bella Mehta bella_mehta ( View Tweet)
Abstracts talking about #RA and JAKs and Biologic comparisons
Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below
@RheumNow https://t.co/jl5S4fLq19
Bella Mehta bella_mehta ( View Tweet)
Abatacept in pts at risk of #RA data from clinical trial.
213 pts, 31 centers.
Pts with multiple autoantibodies improved the most with abatacept.
@rheumnow #EULAR2023 https://t.co/c82jx0cAEq
Bella Mehta bella_mehta ( View Tweet)
Treat early it is also cheaper!
5 yr cost of RA ttmt
€11250 ACPA+ > €3526 ACPA-
bDMARDS users
€44788 ACPA+ > €40896 ACPA-
ACPA- "late" ttmt 46% more expensive
ACPA+ early vs. late = similar costs
@Rheumnow #EULAR23 POS0369 https://t.co/dg9T9fqJDl
Aurelie Najm AurelieRheumo ( View Tweet)
In ERA high BMI is associated with high BMI is assoc with failure to get to Low disease activity. From NORD-STAR RCT. Cdn CATCH cohort in #early #Rheumatoid #arthritis also shows I is associated w less remission and less sustained remission #EULAR2023 @RheumNow POS0324 https://t.co/9EXY8Dyz74
Janet Pope Janetbirdope ( View Tweet)
Predictive model to predict RA status via AI , to know what goes in to model or predictions may change. Ex use of DMARDs https://t.co/fkcEKfZWl8
Janet Pope Janetbirdope ( View Tweet)
We would think that targeted therapies would have reduced GC use in RA.
Well, this is not really the case.
Comaprison of GC use in 1999-2008 vs. 2009-2018
52% of patients remain on GC for>3Mo after initiation & 1/3 still continues after 2 years!
@RheumNow #EULAR23 POS0309 https://t.co/dDkUJFlmEm
Aurelie Najm AurelieRheumo ( View Tweet)
What is the course of clinically suspect arthralgia in CCP+ vs neg? 781 pts, 136 got RA and sl more resolved symptoms. RA developed in both groups ACPA+ develop more rapidly - if resolution, still more MRI + vs neg. #EULAR2023 POS319 @RheumNow Diff patterns of progression
Janet Pope Janetbirdope ( View Tweet)
Weather impacts outcomes in RA: myth or reality? ⛈🌦
Larger study to date 14200 weather-matched PROs
Mean PtP PtF PtGA scores higher in winter
Few meteorological measures significantly correlated w/ PROs, but correlations are weak
@RheumNow #EULAR23 POS0325 https://t.co/7AJmbLQrPW
Aurelie Najm AurelieRheumo ( View Tweet)
REMOTRA; REMote moniToring in pReclinical Arthritis
43pts CSA 6 Mo follow up
Pts acceptance and usage decrease during time (like many other studies using apps)
Composite score of PROs asso w/ risk of RA (...but VPP 12%)
Digital follow up of Pre-RA is not ready for clinic yet. https://t.co/o31dVEa5xt
Aurelie Najm AurelieRheumo ( View Tweet)
Amazing the chatter in the room for this one. The idea that a new JAKi might genuinely outperform existing JAKi in hard-to-treat RA, without safety cost, is particularly enticing.
We all want to see the paper & healthy skepticism of ph2, but watch this space #EULAR2023 @RheumNow https://t.co/jEyk8zqZN8
David Liew drdavidliew ( View Tweet)
